Quantify the Value of Transmural Inflammation in the Treatment of Crohn's Disease With Ustekinumab:an Analysis Based on Imaging Science

Sixth Affiliated Hospital, Sun Yat-sen University150 enrolled

Overview

Crohn's disease(CD),a type of inflammatory bowel disease(IBD), is a chronic intestinal recurrent inflammatory disease involving the entire digestive tract. And Ustekinumab, a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23, is a newly targeted drug approved for the treatment of Crohn's disease in recent years.Based on the high-throughput imaging characteristic analysis technique, this study quantitatively analyzed the transmural inflammation of Crohn's disease, and discussed its prognostic value in the treatment of Ustekinumab, and further analyzed the increment of its relative clinical index.

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Inflammatory Bowel Diseases Crohn Disease Biologics

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Inpatients with Crohn's disease diagnosed in the IBD center of Sixth Affiliated Hospital of Sun Yat-Sen University from January 2020 to June 2022 * Treated with Ustekinumab and followed up regularly for 20 weeks * Complete pre-treatment cross-sectional imaging data (CTE/MRE and US) Exclusion Criteria: * The diagnosis is not clear * Under the age of 18 * Lack of endoscopic and pathological data

Locations (1)

Outcomes

Primary Outcomes

endoscopic remission rate at 12 months

Time frame: 12 months after first intervention administration

normalization rate of serum biomarker at 12 months

Time frame: 12 months after first intervention administration

clinical remission rate at 12 months

Time frame: 12 months after first intervention administration

clinical response rate at 12 months

Time frame: 12 months after first intervention administration

endoscopic response rate at 12 months

Time frame: 12 months after first intervention administration

life quality changes at 12 months

life quality evaluated by CDAI (Crohn's Disease Activity Index) at 12 months

Time frame: 12 months after first intervention administration

endoscopic remission rate after induction therapy